FDA Approves LIALDA (mesalamine), The First Oral Once-Daily Mesalamine For Patients With Active, Mild To Moderate ... (Medical News Today) Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDATM (mesalamine) with MMX(R) technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine. [click link for full article]
Averion Signs Agreement with India CRO Apothecaries to Expand Core Oncology Competencies and Global Presence (Business Wire via Yahoo! Finance) BOSTON----Averion International Corp. , a clinical research organization specializing in oncology, medical devices, dermatology and nephrology, today announced that is has signed a non-exclusive agreement with Apothecaries Ltd. of New Delhi, India, a full-service CRO with a focus on oncology.
ThinSpring Announces Appointment of John G. McGraw as Senior Account Executive for Retail Software Business Unit (PR Web via Yahoo! News) Bridgewater, NJ (PRWeb) January 26, 2007 -- ThinSpring, a leading provider of XML-based solutions such as SPL Server and the United States Food and Drug Administration's (FDA) Electronic Labeling Information Processing System (ELIPS), is announcing that John G.